DGX
$198.61
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
Intraday
Recent News
A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Softness
Event overview and recent stock performance Quest Diagnostics (DGX) has been drawing attention after recent share price moves, with the stock down 0.4% over the past day and 1.3% over the past week, while remaining positive over the past 3 months and over the past year. See our latest analysis for Quest Diagnostics. Short term share price weakness contrasts with firmer momentum over longer periods, with the recent 3 month share price return of 11.35% and 1 year total shareholder return of...
4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts
An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.
Beat the Market the Zacks Way: IPG Photonics, Celanese, Costco in Focus
IPG Photonics has surged 43.1% since a Zacks Rank #1 upgrade, showcasing how the firm's stock-picking approach is beating a volatile market.
Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics Extends Colorectal Screening Reach With Guardant Shield Partnership
Quest Diagnostics (NYSE:DGX) is partnering with Guardant Health to offer Shield, an FDA-approved blood test for colorectal cancer screening, across its nationwide network. The agreement expands access to a non-invasive screening option for eligible patients through Quest collection sites and provider relationships. The Shield test is included in national colorectal cancer screening guidelines and has shown strong adherence rates in clinical use. Quest Diagnostics, a large US clinical...